Here are the DEF 14A proxy statements from Bone Biologics Corp (BBLG) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow BBLG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BBLG filings page.
Bone Biologics Corporation (BBLG) is asking stockholders at the September 28, 2026 annual meeting to elect four directors, approve executive compensation on an advisory basis, and ratify Weinberg & Company, P.A. as independent auditor for 2026.
The company also seeks approval under Nasdaq Listing Rule 5635(d) for the potential issuance of up to 4,352,115 shares of common stock underlying warrants issued in a July 7, 2026 private placement and to the placement agent. As of August 6, 2026, common shares outstanding were 2,011,057. The private placement provided approximately $2.7 million of net proceeds, with up to approximately $6.0 million of additional gross proceeds possible if the Common Warrants are fully exercised for cash.
Stockholders are further asked to authorize a reverse stock split of the common stock within a range of 1‑for‑2 to 1‑for‑10, at the Board’s discretion and without reducing the 100,000,000 authorized shares, and to approve potential adjournment of the meeting if needed to secure sufficient votes or a quorum.
Bone Biologics Corporation has called its 2026 Annual Meeting of Stockholders for August 11, 2026 at its Burlington, Massachusetts headquarters. Shareholders are being asked to elect four directors, approve on an advisory basis executive officer compensation, and ratify Weinberg & Company, P.A. as independent auditor for 2026.
Holders of 1,795,260 shares of common stock as of June 12, 2026 may vote by internet, telephone, mail or in person. The board recommends voting “FOR” all director nominees and “FOR” the say-on-pay and auditor ratification proposals. The proxy also details executive and director pay, performance-based bonuses, stock option grants and audit fees.